Soligenix halts Phase 3 FLASH2 HyBryte trial in CTCL for futility
PUBT · 12h ago
Share
Listen to the news
- Soligenix reported interim results from pivotal Phase 3 FLASH2 trial of HyBryte in cutaneous T-cell lymphoma.
- Data Monitoring Committee recommended halting study for futility, citing lack of efficacy signal versus expectations from prior trial.
- Management plans additional data review to assess whether any patient subgroups may still benefit.
- Company flagged strategic review, citing about $5.9 million in cash.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604280730PR_NEWS_USPR_____PH43420) on April 28, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved